Clay Siegall- Working to Better Drug Treatments

The founder and CEO of Seattle Genetics, Dr. Clay Siegall has been making an impact in the business world for quite some time. He has spent much of his time focusing on fighting disease through the production of drugs that fight sickness in a unique way. Clay Siegall recently sat down with inspirery to share insight into his success and what drives him each day.


Clay Siegall was inspired to began business out of an interesting situation. Growing up he always had an interest in medicine and technology. In particular he was always curious as to how nature would intervene to stop disease. This interest was increased when a family member diagnosed nearly died as a result of the chemotherapy treatment they were receiving. Siegall began researching possible solutions for the problem and this ultimately led to the business he does today.


Siegall’s company, Seattle Genetics makes money from selling thier own, proprietary drugs. His first drug ADCetris has done very well. The drug itself was the first FDA-approved antibody drug conjugate. Furthermore the company also makes quite an earning from partnerships as well as licensing certain technologies that the company has developed themselves. The company had done quite well but the success did not come over night. It took Seattle Genetics nearly ten years before becoming profitable. Siegall credits his hard work ethic as the ultimate reason for success.


Co-founder of Seattle Genetics Dr. Clay Siegall has worked hard to reach his current success. He holds two degrees including a B.S. in zoology from The University of Maryland and a Ph.D from George Washington University. Under his leadership, Seattle Genetics has built a tremendous group of cancer therapies. Before and During the time he worked with Seattle Genetics he has partnered with a number of well known groups including National Cancer Institute, Bristol-Myers Squibb Pharmaceutical Research Institute and the National Institutes of Health. He is also an accomplished author with more than seventy publications.

Leave a Reply

Your email address will not be published. Required fields are marked *